Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 233

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial

Wang, Weijia, He, Shanzhi, Zhang, Wenli, Zhang, Hongyu, DeStefano, Vincent M, Wada, Masayuki, Pinz, Kevin, Deener, Greg, Shah, Darshi, Hagag, Nabil, Wang, Min, Hong, Ming, Zeng, Ronghao, Lan, Ting, Ma, Yu, Li, Fugui, Liang, Yingwen, Guo, Zhencong, Zou, Chanjuan, Wang, Mingxia, Ding, Ling, Ma, Yupo, Yuan, Yong · 2024 · Annals of the Rheumatic Diseases

Abstract

Objectives This study aims to evaluate the safety and efficacy of BCMA-CD19 compound chimeric antigen receptor T cells (cCAR) to dual reset the humoral and B cell immune system in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN). Methods This is a single-arm open-label multicentre phase 1 study of BCMA and CD19-directed cCAR in patients suffering from SLE/LN with autoantibodies produced by B cells and plasma/long-lived plasma cells. In this clinical trial, we sequentially assigned biopsy-confirmed (classes III–V) LN patients to receive 3×106 cCAR cells/kg postcessation of all SLE medications and conditioning. The primary endpoint of safety and toxicity was assessed. Complete immune reset was indicated by B cell receptor (BCR) deep sequencing and flow cytometry analysis. Patient 11 (P11) had insufficient lymphocyte counts and was underdosed as compassionate use. Results P1 and P2 achieved symptom and medication-free remission (MFR) from SLE and complete remission from lymphoma. P3–P13 (excluding P11) received an initial dose of 3×106 cCAR cells /kg and were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR and the complement returned to normal levels. These patients achieved symptom and MFR with post-cCAR follow-up to 46 months. Complete recovery of B cells was seen in 2–6 months post-cCAR. Mean SLE Disease Activity Index 2000 reduced from 10.6 (baseline) to 2.7 (3 months), and renal function significantly improved in 10 LN patients ≤90 days post-cCAR. cCAR T therapy was well tolerant with mild cytokine-release syndrome. Conclusions Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ard-2024-225785

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 233

Metadata

Authors
Wang, W., He, S., Zhang, W., Zhang, H., DeStefano, V. M., Wada, M., Pinz, K., Deener, G., Shah, D., Hagag, N., Wang, M., Hong, M., Zeng, R., Lan, T., Ma, Y., Li, F., Liang, Y., Guo, Z., Zou, C., Wang, M., Ding, L., Ma, Y., & Yuan, Y.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2024-10
Volume
83
Issue
10
Pages
1304-1314
ISSN
0003-4967 (ISSN-L)
OpenAlex
W4398200122
Cited by
233
References
3
FWCI
35.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. https://app.cochat.ai/papers/10.1136/ard-2024-225785
The paper
Wang, W., He, S., Zhang, W., Zhang, H., DeStefano, V. M., Wada, M., Pinz, K., Deener, G., Shah, D., Hagag, N., Wang, M., Hong, M., Zeng, R., Lan, T., Ma, Y., Li, F., Liang, Y., Guo, Z., Zou, C., . . . Yuan, Y. (2024). BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2024-225785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.